Legal & General Group Plc Buys Shares of 173,267 Omnicell, Inc. $OMCL

Legal & General Group Plc purchased a new position in Omnicell, Inc. (NASDAQ:OMCL) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 173,267 shares of the company’s stock, valued at approximately $7,194,000. Legal & General Group Plc owned about 0.38% of Omnicell at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Raymond James Financial Inc. bought a new stake in shares of Omnicell during the 2nd quarter worth $26,000. Versant Capital Management Inc increased its stake in Omnicell by 38.7% in the second quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock valued at $44,000 after acquiring an additional 294 shares during the last quarter. Clearstead Advisors LLC raised its position in Omnicell by 12,180.0% during the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after purchasing an additional 1,218 shares in the last quarter. Kemnay Advisory Services Inc. bought a new stake in Omnicell during the fourth quarter worth about $58,000. Finally, Parkside Financial Bank & Trust lifted its stake in Omnicell by 1,708.1% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock worth $61,000 after purchasing an additional 1,264 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Trading Up 0.6%

NASDAQ:OMCL opened at $34.71 on Thursday. The firm has a market capitalization of $1.58 billion, a P/E ratio of 41.32, a P/E/G ratio of 0.87 and a beta of 0.97. The company has a quick ratio of 1.43, a current ratio of 1.64 and a debt-to-equity ratio of 0.13. The company has a fifty day moving average of $39.55 and a 200 day moving average of $39.29. Omnicell, Inc. has a 52 week low of $29.06 and a 52 week high of $55.00.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.47. The business had revenue of $312.21 million for the quarter, compared to analyst estimates of $310.21 million. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The company’s revenue was up 7.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. On average, research analysts predict that Omnicell, Inc. will post 1.41 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on OMCL. Weiss Ratings raised Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 18th. Wells Fargo & Company lowered their price objective on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Piper Sandler reaffirmed an “overweight” rating and issued a $45.00 price objective (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. KeyCorp reaffirmed an “overweight” rating on shares of Omnicell in a report on Monday, August 24th. Finally, Zacks Research cut shares of Omnicell from a “hold” rating to a “strong sell” rating in a research report on Friday, August 7th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $57.86.

Omnicell Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.